Titan Pharmaceuticals Provides Update On Parkinson's Disease Clinical Development Program July 2, 2018
Titan Pharmaceuticals And Braeburn Announce Mutual Termination Of License Agreement For Probuphine® For Opioid Dependence May 30, 2018
Accomplished Global Pharmaceutical Executive, Federico Seghi Recli, Appointed To Titan's Board May 14, 2018
Titan Pharmaceuticals Schedules Conference Call To Review Fourth Quarter And Full Year 2017 Financial Results March 26, 2018
Titan Executes Agreement For Acquisition By Molteni Of Probuphine® In Europe And Other Select Territories March 21, 2018
